Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiGene Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757971

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757971

Andersen-Tawil Syndrome (ATS)

PUBLISHED:
PAGES: 276 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Andersen-Tawil Syndrome (ATS) Market to Reach US$3.1 Million by 2030

The global market for Andersen-Tawil Syndrome (ATS) estimated at US$2.2 Million in the year 2024, is expected to reach US$3.1 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Type 1 Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.8 Million by the end of the analysis period. Growth in the Type 2 Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$599.5 Thousand While China is Forecast to Grow at 8.7% CAGR

The Andersen-Tawil Syndrome (ATS) market in the U.S. is estimated at US$599.5 Thousand in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$610.9 Thousand by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Andersen-Tawil Syndrome (ATS) Market - Key Trends & Drivers Summarized

Why Is Andersen-Tawil Syndrome Garnering Increased Attention in the Rare Disease Community?

Andersen-Tawil Syndrome (ATS), though extremely rare, is drawing growing interest from researchers, clinicians, and patient advocacy groups due to its complex symptomology and diagnostic challenges. This autosomal dominant disorder-characterized by a triad of periodic paralysis, distinctive facial and skeletal features, and cardiac arrhythmias-presents significant hurdles for early detection and effective management. Traditionally underdiagnosed or misclassified due to overlapping symptoms with more common conditions, ATS is now increasingly being recognized thanks to advances in genetic testing and clinical awareness. The emergence of more refined phenotyping techniques and next-generation sequencing has improved diagnostic accuracy, making it easier to distinguish ATS from other neuromuscular or cardiac disorders. This has contributed to a steady rise in identified cases worldwide, prompting a more focused approach to research and care.

Furthermore, the rare disease community’s efforts to push for earlier diagnosis and targeted treatment for orphan diseases are having a direct impact on ATS awareness. Patient advocacy groups are playing a pivotal role in disseminating educational resources, supporting early intervention strategies, and connecting affected families with specialized care centers. Public health agencies, too, are investing more in rare disease registries, which are helping build comprehensive datasets on conditions like ATS. These registries not only improve epidemiological understanding but also guide research into genotype-phenotype correlations and long-term disease progression. Clinicians are now more frequently encouraged to consider ATS in patients presenting with unexplained episodes of muscle weakness alongside ECG abnormalities or dysmorphic features. As a result, ATS is transitioning from being a medical enigma to a well-recognized syndrome within the neuromuscular and cardiology communities, setting the stage for more targeted therapeutic and diagnostic solutions.

How Are Diagnostic Tools and Genetic Insights Transforming ATS Management Strategies?

The landscape for diagnosing and managing Andersen-Tawil Syndrome is evolving rapidly, thanks in large part to the growing integration of molecular genetics and precision medicine. At the heart of ATS lies a mutation in the KCNJ2 gene, which encodes a potassium ion channel involved in regulating both muscle contraction and cardiac rhythm. Identifying this mutation through genetic testing has become a cornerstone of ATS diagnosis, enabling clinicians to confirm suspected cases with a high degree of certainty. Genetic testing is now more widely available and affordable, helping detect familial patterns and guiding risk assessment for asymptomatic relatives. This has led to an increase in pre-symptomatic diagnoses, which is critical for early cardiac monitoring and intervention, given the life-threatening potential of arrhythmias associated with the disorder.

Beyond diagnosis, genetic insights are also influencing treatment approaches. By understanding the molecular mechanisms underlying ATS, researchers are exploring targeted therapies that modulate ion channel function. Although no cure currently exists, individualized treatment plans are becoming more common, incorporating a mix of lifestyle modifications, pharmacological interventions, and cardiac surveillance. For example, potassium supplementation is used to manage periodic paralysis, while antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs) are prescribed in patients with severe cardiac manifestations. Advances in wearable health technology have further improved management, allowing real-time monitoring of cardiac activity and muscle performance. These tools not only provide early warnings for serious events but also facilitate long-term data collection, contributing to research and personalized care. This fusion of genetics, diagnostics, and technology is revolutionizing the way ATS is approached, making management more proactive rather than reactive.

What Challenges and Opportunities Exist in the Development of ATS Therapeutics?

Developing effective therapeutics for Andersen-Tawil Syndrome presents a unique mix of obstacles and emerging possibilities, largely due to the syndrome’s rarity and clinical variability. One of the foremost challenges lies in the small and dispersed patient population, which makes it difficult to conduct large-scale clinical trials and gather statistically significant data. The heterogeneous nature of the disease-where symptoms can range widely in type, severity, and frequency-further complicates the creation of standardized treatment protocols. Moreover, the overlap of ATS symptoms with other disorders often delays diagnosis, reducing the window for early therapeutic intervention. Limited commercial incentives have historically discouraged major pharmaceutical players from investing heavily in ATS-specific drug development, leading to a reliance on off-label use of drugs intended for other conditions.

Despite these barriers, there is a growing wave of optimism driven by the expanding rare disease drug ecosystem. Advances in drug repurposing are enabling researchers to evaluate existing ion channel modulators and antiarrhythmic agents for efficacy in ATS patients. This strategy significantly reduces development timelines and costs, making it more feasible to bring treatments to market. In parallel, patient registries and international collaborations are helping to consolidate data and resources, creating a more unified research front. Regulatory bodies are also providing pathways like orphan drug designations and accelerated approval processes to incentivize innovation in this space. Emerging technologies such as CRISPR-based gene editing and RNA-targeted therapies, while still in early stages, hold potential for long-term correction of the underlying genetic mutation. These developments signal a paradigm shift, suggesting that despite its challenges, the ATS therapeutic landscape is on the cusp of meaningful change, driven by science, policy, and patient advocacy.

Which Factors Are Driving Growth in the Andersen-Tawil Syndrome Market?

The growth in the Andersen-Tawil Syndrome market is driven by several critical factors linked to advances in diagnostics, increasing awareness, expanding therapeutic exploration, and supportive healthcare policy. At the forefront is the role of genetic testing, which has dramatically improved the identification of ATS cases. As sequencing technologies become more accessible and are integrated into standard diagnostic protocols, more patients are being correctly diagnosed, even during asymptomatic phases. This not only increases the overall diagnosed prevalence of the condition but also brings a larger patient population into the healthcare system, stimulating demand for medical consultations, monitoring tools, and therapeutic options. At the same time, the rise in multidisciplinary care approaches-bringing together neurologists, cardiologists, and geneticists-is elevating the quality of care available for ATS patients, further reinforcing the growth of associated markets such as diagnostics, cardiac implants, and rare disease therapeutics.

Public and private sector interest in rare diseases is another major driver. Governments are introducing initiatives to support orphan disease treatment, including funding programs, research grants, and access to regulatory incentives. This support has encouraged biotech startups and mid-sized pharmaceutical firms to enter the ATS space, developing novel drug candidates or adapting existing therapies. Meanwhile, global patient advocacy is reshaping the market by ensuring that patient voices influence research priorities, clinical trial design, and funding allocations. The integration of digital health tools-such as remote ECG monitors and patient data apps-is also expanding market opportunities by enabling ongoing symptom tracking, early intervention, and real-world evidence collection. Furthermore, educational efforts targeted at primary care providers are increasing early recognition of ATS symptoms, which leads to faster referrals and better patient outcomes. These interlinked forces are not only driving steady growth in the ATS market but are also setting the foundation for long-term, patient-centric innovation in rare disease care.

SCOPE OF STUDY:

The report analyzes the Andersen-Tawil Syndrome (ATS) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Type 1 Disease, Type 2 Disease); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Advanz Pharma
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36163

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Andersen-Tawil Syndrome (ATS) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Accuracy Spur Early Identification and Clinical Management of Andersen-Tawil Syndrome (ATS)
    • Advancements in Genetic Testing Technologies Strengthen the Business Case for Precision Diagnosis in Rare Channelopathies
    • Here's How Increased Inclusion of ATS in Neuromuscular Disease Panels Expands the Addressable Patient Pool
    • Growing Interest in Potassium Channelopathies Drives Research into Targeted Therapeutic Approaches for ATS
    • Here's the Story: Integration of Cardiac Monitoring and Neurological Assessment Enhances Holistic Management Strategies
    • Improved Access to Multidisciplinary Care Models Sustains Growth in Specialist Referral and Treatment Uptake
    • Rising Use of Off-Label Therapies and Symptom-Based Management Drives Demand for Personalized Care Plans
    • Global Expansion of Orphan Drug Programs Generates Opportunities for Novel ATS-Specific Therapeutics
    • Technological Innovation in Wearable ECG and Remote Monitoring Tools Supports Early Detection of Arrhythmic Events
    • Growing Focus on Pediatric Neurology and Genetic Counseling Strengthens Early Intervention Strategies for ATS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Andersen-Tawil Syndrome (ATS) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Type 1 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Type 2 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!